Kymera Therapeutics (KYMR) Misses Q1 EPS by 5c

Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.05 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $9.62 million versus the consensus estimate of $16.23 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Lennar Corp. (LEN) Misses Q2 EPS by 1c